Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 18/20 | 0.80 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4593926 | 0.89 | IDO1 (1.00) | IDO1CHRM5 | |
| SCHEMBL20912425 | 0.86 | IDO1 (0.79) | IDO1 | |
| SCHEMBL24777808 | 0.82 | IDO1 (0.72) | IDO1CYP3A4CXCR3 | |
| SCHEMBL20912413 | 0.82 | IDO1 (0.78) | IDO1 | |
| SCHEMBL19456573 | 0.81 | IDO1 (0.77) | IDO1 | |
| SCHEMBL20597235 | 0.80 | IDO1 (0.66) | IDO1CYP3A4CXCR3 | |
| SCHEMBL19456591 | 0.80 | IDO1 (0.66) | IDO1CYP3A4CXCR3 | |
| SCHEMBL19456420 | 0.80 | IDO1 (0.78) | IDO1 | |
| SCHEMBL20597091 | 0.79 | IDO1 (0.66) | IDO1 | |
| SCHEMBL19456598 | 0.79 | IDO1 (0.66) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669273-B2 | Use of aza-tryptanthrin derivatives as inhibitors of IDO1 and/or TDO | PEKING UNIVERSITY (CN) | 2020-06-02 | — | — | US | disclosed |
| US-20190112308-A1 | Use of Aza-Tryptanthrin Derivatives as Inhibitors of IDO1 and/or TDO | PEKING UNIVERSITY (CN) | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669273-B2 | Use of aza-tryptanthrin derivatives as inhibitors of IDO1 and/or TDO | IDO1, TDO2, IDO2 | IDO1 1/4885CHRM5 1374/4885CYP3A4 159/4885 |
| US-20190112308-A1 | Use of Aza-Tryptanthrin Derivatives as Inhibitors of IDO1 and/or TDO | IDO1, TDO2, IDO2 | IDO1 1/4885CHRM5 1374/4885CYP3A4 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.